Annexin A1: potential for glucocorticoid sparing in RA
Review published in Nature reviews. Rheumatology (2013)
Abstract
Glucocorticoids have broad-ranging and powerful anti-inflammatory and immunomodulatory effects. Unsurprisingly, therefore, glucocorticoids are widely and persistently used to treat a large number of inflammatory diseases, including rheumatoid arthritis (RA), despite the well-described adverse effects of these drugs. Annexin A1 is a glucocorticoid-induced molecule that is known to replicate many of the described anti-inflammatory effects of glucocorticoids. In addition to the well-documented roles of this protein in neutrophil function, emerging evidence suggests that annexin A1 is involved in the modulation of T-cell function and the adaptive immune responses relevant to RA. Interest in annexin A1 was renewed after the delineation of the receptors for this protein. This breakthrough also led to advances in our understanding of anti-inflammatory annexin A1 mimetic peptides and agonistic compounds targeting these receptors, particularly those specific for the receptor N-formyl peptide receptor 2 (FPR2). Herein, we review the current knowledge of the biological activities of annexin A1 and their relevance to RA pathogenesis. We also discuss the potential of annexin A1 mimics and strategies aimed at potentiating annexin A1 signalling to become viable approaches to minimizing glucocorticoid use in RA and other inflammatory disorders.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Glucocorticoids have broad-ranging and powerful anti-inflammatory and immunomodulatory effects.
Por qué esto importa para la hirudoterapia
Esta revisión examina las actividades biológicas de la Anexina A1, una proteína antiinflamatoria inducida por glucocorticoides que modula la función de los linfocitos T, explorando su potencial para minimizar el uso de glucocorticoides en el tratamiento de la artritis reumatoide. El artículo analiza mecanismos proteicos, receptores FPR2, y péptidos miméticos de la Anexina A1 y compuestos agonistas sin hacer referencia alguna a sanguijuelas ni a moléculas derivadas de sanguijuelas. El estudio no evalúa la hirudoterapia. Por lo tanto, su relevancia para la American Society of Hirudotherapy es completamente indirecta, limitada al contexto más amplio de las estrategias terapéuticas antiinflamatorias.
Citación
Annexin A1: potential for glucocorticoid sparing in RA
Yang YH et al. · Nature reviews. Rheumatology, 2013
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026